Pharmafile Logo
Pharmafocus logo
Advanced Search

acalabrutinib

Showing 4 posts of 4 posts found.

astrazeneca_plaque

AstraZeneca admits cancer data for acquired drug was fabricated

October 16, 2017
Research and Development, Sales and Marketing Acerta, AstraZeneca, acalabrutinib

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers …

News
astrazeneca_building_white

AstraZeneca scores second accelerated FDA review in 2 days for blood cancer drug

August 1, 2017
Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, acalabrutinib, biotech, drugs, life sciences, pharma, pharmaceutical

It’s been a rollercoaster week for AstraZeneca.

News

AstraZeneca to buy majority share in Acerta Pharma

December 17, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers

Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …

News
AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024